At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 15 Jan 2003 A preclinical study has been added to the Anxiety disorders pharmacodynamics section
- 07 May 2001 Preclinical development for Anxiety disorders in USA (Unknown route)